Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors

Clinical trial NCT07583654 · RECRUITING

Trial details

NCT number: NCT07583654
Sponsor: West China Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

mRNA Vaccine Solid Tumor Cancer Peptides Cancer Metastatic

Start date: 2026-07-13
Primary completion: 2027-06-30
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.